International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?
Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2020-02-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/6/1/00159-2019.full |
| _version_ | 1811323608512856064 |
|---|---|
| author | Paul Martin Putora Pawel Leskow Fiona McDonald Tim Batchelor Matthiew Evison |
| author_facet | Paul Martin Putora Pawel Leskow Fiona McDonald Tim Batchelor Matthiew Evison |
| author_sort | Paul Martin Putora |
| collection | DOAJ |
| description | Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT followed by adjuvant immunotherapy (dependent on programmed death ligand 1 status). As there is no clear evidence demonstrating a survival benefit between these options, patient preference plays an important role. A lack of a consensus definition of resectability of N2 disease adds to the complexity of the decision-making process. We compared 10 international guidelines on the treatment of NSCLC to investigate the recommendations on preoperatively diagnosed stage III N2 NSCLC. This comparison simplified the treatment paths to multimodal therapy based on surgery or radiotherapy (RT). We analysed factors relevant to decision-making within these guidelines. Overall, for nonbulky mediastinal lymph node involvement there was no clear preference between surgery and CRT. With increasing extent of mediastinal nodal disease, a tendency towards multimodal treatment based on RT was identified. In multiple scenarios, surgery or RT-based treatments are feasible and patient involvement in decision-making is critical. |
| first_indexed | 2024-04-13T13:58:12Z |
| format | Article |
| id | doaj.art-eb5cd13192b84999a9bb060ec1a3d13e |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-04-13T13:58:12Z |
| publishDate | 2020-02-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-eb5cd13192b84999a9bb060ec1a3d13e2022-12-22T02:44:07ZengEuropean Respiratory SocietyERJ Open Research2312-05412020-02-016110.1183/23120541.00159-201900159-2019International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?Paul Martin Putora0Pawel Leskow1Fiona McDonald2Tim Batchelor3Matthiew Evison4 Dept of Radiation Oncology, Kantonsspital St Gallen, St Gallen, Switzerland Dept of Thoracic Surgery, Kantonsspital St Gallen, St Gallen, Switzerland Dept of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK Dept of Thoracic Surgery, University Hospitals Bristol NHS Foundation Trust, Bristol, UK Manchester Thoracic Oncology Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT followed by adjuvant immunotherapy (dependent on programmed death ligand 1 status). As there is no clear evidence demonstrating a survival benefit between these options, patient preference plays an important role. A lack of a consensus definition of resectability of N2 disease adds to the complexity of the decision-making process. We compared 10 international guidelines on the treatment of NSCLC to investigate the recommendations on preoperatively diagnosed stage III N2 NSCLC. This comparison simplified the treatment paths to multimodal therapy based on surgery or radiotherapy (RT). We analysed factors relevant to decision-making within these guidelines. Overall, for nonbulky mediastinal lymph node involvement there was no clear preference between surgery and CRT. With increasing extent of mediastinal nodal disease, a tendency towards multimodal treatment based on RT was identified. In multiple scenarios, surgery or RT-based treatments are feasible and patient involvement in decision-making is critical.http://openres.ersjournals.com/content/6/1/00159-2019.full |
| spellingShingle | Paul Martin Putora Pawel Leskow Fiona McDonald Tim Batchelor Matthiew Evison International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Research |
| title | International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? |
| title_full | International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? |
| title_fullStr | International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? |
| title_full_unstemmed | International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? |
| title_short | International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? |
| title_sort | international guidelines on stage iii n2 nonsmall cell lung cancer surgery or radiotherapy |
| url | http://openres.ersjournals.com/content/6/1/00159-2019.full |
| work_keys_str_mv | AT paulmartinputora internationalguidelinesonstageiiin2nonsmallcelllungcancersurgeryorradiotherapy AT pawelleskow internationalguidelinesonstageiiin2nonsmallcelllungcancersurgeryorradiotherapy AT fionamcdonald internationalguidelinesonstageiiin2nonsmallcelllungcancersurgeryorradiotherapy AT timbatchelor internationalguidelinesonstageiiin2nonsmallcelllungcancersurgeryorradiotherapy AT matthiewevison internationalguidelinesonstageiiin2nonsmallcelllungcancersurgeryorradiotherapy |